Key result
Antihypertensive treatments evaluated for death and graft loss in kidney transplant recipients.
Why the study?
The comparative effects of specific blood pressure-lowering treatments on patient-important outcomes following kidney transplantation remained uncertain.
Does antihypertensive treatment reduce all-cause death and graft loss, and improve kidney function in kidney transplant recipients?
Population
Recipients of a functioning kidney transplant for at least two weeks
Comparison
Different classes and combinations of antihypertensive drugs vs each other, placebo, or standard care alone
Design
Systematic review and meta-analysis of RCTs and quasi-RCTs
Authors
Loading...
CCBs merit first-line use to reduce death and graft loss in kidney recipients; extends limited RCT evidence while leaving ARB/ACEI effects uncertain.
Systematic Review
Does antihypertensive treatment reduce all-cause death and graft loss, and improve kidney function in kidney transplant recipients?
In kidney transplant recipients, calcium channel blockers probably reduce death and graft loss, and ARBs may reduce graft loss compared to placebo or standard care.
Natale et al. (2024) conducted a systematic review in Kidney transplant recipients. Antihypertensive treatment (e.g., CCB, ACEi, ARB) vs. Placebo, standard care, or other antihypertensive agents was evaluated on All-cause death and graft loss. This systematic review evaluated the effects of various antihypertensive treatments on all-cause death, graft loss, and other clinical outcomes in kidney transplant recipients.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: